Doctors' opinions of information provided by Libyan pharmaceutical company representatives

Libyan Journal of Medicine

Volumn 7, Issue 1, 2012, Pages

  Alssageer, Mustafa A ^a   Kowalski, Stefan R ^b  

^a SEBHA UNIVERSITY   (Libyan Arab Jamahiriya)

^b UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

Author keywords

Drug detailing; Drug information; Pharmaceutical company representative

Indexed keywords

ADULT; ADVERSE DRUG REACTION; ARTICLE; CONTROLLED STUDY; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG INDUSTRY; DRUG INFORMATION; DRUG INTERACTION; DRUG QUALITY; DRUG SAFETY; DRUG SUBSTITUTION; FEMALE; HUMAN; LIBYAN ARAB JAMAHIRIYA; MALE; PHYSICIAN; QUESTIONNAIRE; TREATMENT INDICATION;

EID: 84871476756     PISSN: 19932820     EISSN: 18196357     Source Type: Journal    
DOI: 10.3402/ljm.v7i0.19708     Document Type: Article

References (32)

1. Roughead EE. The pharmaceutical representative and medical practitioner encounter: implications for quality use of medicines (dissertation). Victoria: La Trobe University; 1995.
2. Spurling GK, Mansfield PR, Montgomery BD, Lexchin J, Doust J, Othman N, et al. Information from pharmaceutical companies and the quality, quantity, and cost of physicians' prescribing: a systematic review. PLoS Med. 2010; 7: e1000352.
3. Ben Abdelaziz A, Harrabi I, Rahmani S, Ghedira A, Gaha K, Ghannem H. [Attitudes of general practitioners to pharmaceutical sales representatives in Sousse]. East Mediterr Health J. 2003; 9: 1075-1083.
4. Kisa S. Factors that influence prescribing decisions among Turkish physicians. Clin Res Regul Aff. 2006; 23: 177-189.
5. Layton MR, Sritanyarat W, Chadbunchachai S, Wertheimer AI. Sources of information for new drugs among physicians in Thailand. Pharm World Sci. 2007; 29: 619-627.
6. Magzoub MA, Neyaz Y, Khoja T, Qureshi NA, Haycox A, Walley T. Determinants of physicians' medication prescribing behaviour in primary care in Riyadh City, Saudi Arabia. East Mediterr Health J. 2011; 17: 16
7. World Health Organization. Ethical criteria for medicinal drug promotion. Geneva: World Health Organization; 1988. Available from: http://www.who.int/medicinedocs [cited 3 August 2008].
8. Othman N, Vitry AI, Roughead EE, Ismail SB, Omar K. Medicines information provided by pharmaceutical representatives: a comparative study in Australia and Malaysia. BMC Public Health. 2010; 10: 743.
9. Roughead EE, Gilbert AL, Harvey KJ. Self-regulatory codes of conduct: are they effective in controlling pharmaceutical representatives' presentations to general medical practitioners? Int J Health Serv. 1998; 28: 269-279.
10. Hemminki E. Content analysis of drug-detailing by pharmaceutical representatives. Med Educ. 1977; 11: 21
11. Steinman MA, Harper GM, Chren MM, Landefeld CS, Bero LA. Characteristics and impact of drug detailing for gabapentin. PLoS Med. 2007; 4: e134.
12. Ziegler MG, Lew P, Singer BC. The accuracy of drug information from pharmaceutical sales representatives. JAMA. 1995; 273: 129
13. Rohra DK, Gilani AH, Memon IK, Perven G, Khan MT, Zafar H, et al. Critical evaluation of the claims made by pharmaceutical companies in drug promotional material in Pakistan. J Pharm Pharm Sci. 2006; 9: 5
14. Kerr SJ, Mant A, Horn FE, McGeechan K, Sayer GP. Lessons from early large-scale adoption of celecoxib and rofecoxib by Australian general practitioners. Med J Aust. 2003; 179: 40
15. Hawkes N. GlaxoSmithKline pays $3bn to settle dispute over rosiglitazone and other drugs. BMJ. 2011; 343: d7234.
16. Alssageer MA, Kowalski SR. A survey of pharmaceutical company representative interactions with doctors in Libya. Libyan J Med. 2012; 7. DOI: 10.3402/ljm.v7i0.18556
17. Idris KM, Mustafa AF, Yousif MA. Pharmaceutical representatives' beliefs and practices about their professional practice: a study in Sudan. East Mediterr Health J. 2012; 18: 82
18. Roy N, Madhiwalla N, Pai SA. Drug promotional practices in Mumbai: a qualitative study. Indian J Med Ethics. 2007; 4: 57-61.
19. Parker RS, Pettijohn CE. Pharmaceutical drug marketing strategies and tactics: a comparative analysis of attitudes held by pharmaceutical representatives and physicians. Health Mark Q. 2005; 22: 27-43.
20. Sales representatives: a damning report by Prescrire reps monitoring network. Prescrire Int. 1999; 8: 8
21. GlaxoSmithKline. GSK Code of Practice for Promotion and Customer Interactions. London, United Kingdom: GSK; 2010. Available from: http://www.gsk.com/responsibility/downloads/ GSK-Code-of-Practice.pdf [cited 2 July 2012].
22. Prosser H, Almond S, Walley T. Influences on GPs' decision to prescribe new drugs*the importance of who says what. Fam Pract. 2003; 20: 6
23. Strang D, Gagnon M, Molloy W, Bedard M, Darzins P, Etchells E. National survey on the attitudes of Canadian physicians towards drug-detailing by pharmaceutical representatives. Ann R Coll Physicians Surg Can. 1996; 29: 47
24. Tengilimoǧlu D, Korkmaz S, Akinci F, Parsons AL. Managerial implications of medical sales representative perceptions of job duties, job qualifications, and other performance-related issues. Health Mark Q. 2004; 22: 3-26.
25. Fox S. Incentive compensation plan diagnosis in the pharmaceutical industry. Next Generation Pharmaceutical. Available from: http://www.ngpharma.com/article/Pharmaceutical-Marketing- After-the-Gold-Rush [cited October 2008].
26. Hemminki E, Pesonen T. The function of drug company representatives. Scand J Soc Med. 1977; 5: 105-114.
27. Andaleeb SS, Tallman RF. Physician attitudes toward pharmaceutical sales representatives. Health Care Manage Rev. 1995; 20: 68-76.
28. Al-Areefi MA, Hassali MA, Izham M. A qualitative study exploring medical representatives' views on current drug promotion techniques in Yemen. J Med Mark. 2012; 12: 14
29. Lagace RR, Twible JL. The impact of source credibility characteristics on physicians' satisfaction with pharmaceutical salespeople. J Ambul Care Mark. 1991; 4: 53-63.
30. World Health Organization. How to develop and implement a national drug Policy. 2nd ed. Geneva: WHO; 2001.
31. Wazana A. Physicians and the pharmaceutical industry: is a gift ever just a gift? JAMA. 2000; 283: 373-380.
32. Libyan Ministry of Health. Libyan Health Law act number 106 of 1973. Available from: http://www.health.gov.ly/web/ index.php?option-com-docman&task-cat-view&gid-35&dir -DESC&order-date&limit-10&limitstart-10 [cited 13 June 2006].